JP2024524288A5 - - Google Patents

Info

Publication number
JP2024524288A5
JP2024524288A5 JP2023579443A JP2023579443A JP2024524288A5 JP 2024524288 A5 JP2024524288 A5 JP 2024524288A5 JP 2023579443 A JP2023579443 A JP 2023579443A JP 2023579443 A JP2023579443 A JP 2023579443A JP 2024524288 A5 JP2024524288 A5 JP 2024524288A5
Authority
JP
Japan
Prior art keywords
atp
administered
adenosine triphosphate
day
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023579443A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024524288A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/034510 external-priority patent/WO2022271813A1/en
Publication of JP2024524288A publication Critical patent/JP2024524288A/ja
Publication of JP2024524288A5 publication Critical patent/JP2024524288A5/ja
Pending legal-status Critical Current

Links

JP2023579443A 2021-06-22 2022-06-22 アデノシン三リン酸(atp)を含む組成物および認知機能に対する使用方法 Pending JP2024524288A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163213378P 2021-06-22 2021-06-22
US63/213,378 2021-06-22
PCT/US2022/034510 WO2022271813A1 (en) 2021-06-22 2022-06-22 Compositions containing adenosine triphosphate (atp) and methods of use for cognitive function

Publications (2)

Publication Number Publication Date
JP2024524288A JP2024524288A (ja) 2024-07-05
JP2024524288A5 true JP2024524288A5 (cg-RX-API-DMAC10.html) 2025-06-30

Family

ID=84544774

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023579443A Pending JP2024524288A (ja) 2021-06-22 2022-06-22 アデノシン三リン酸(atp)を含む組成物および認知機能に対する使用方法

Country Status (12)

Country Link
US (1) US20240299435A1 (cg-RX-API-DMAC10.html)
EP (1) EP4358972A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024524288A (cg-RX-API-DMAC10.html)
CN (1) CN117835985A (cg-RX-API-DMAC10.html)
AU (1) AU2022297444A1 (cg-RX-API-DMAC10.html)
CA (1) CA3224861A1 (cg-RX-API-DMAC10.html)
CL (1) CL2023003882A1 (cg-RX-API-DMAC10.html)
CO (1) CO2024000517A2 (cg-RX-API-DMAC10.html)
EC (1) ECSP24004256A (cg-RX-API-DMAC10.html)
MX (1) MX2024000145A (cg-RX-API-DMAC10.html)
PE (1) PE20241617A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022271813A1 (cg-RX-API-DMAC10.html)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000095695A (ja) * 1998-07-23 2000-04-04 Nippon Koutai Kenkyusho:Kk 精神分裂病治療薬
US20030069203A1 (en) * 2001-06-04 2003-04-10 Lee Steve S. Method for increasing human performance by reducing muscle fatigue and recovery time through oral administration of adenosine triphosphate
US7629329B2 (en) * 2001-06-04 2009-12-08 Tsi Health Sciences, Inc. Method for increasing muscle mass and strength through administration of adenosine triphosphate
US20050261239A1 (en) * 2004-05-23 2005-11-24 Universiteit Van Maastricht Use of ATP for the manufacture of a medicament for treating certain inflammatory conditions, oxidative stress and fatigue
KR101424833B1 (ko) * 2006-06-27 2014-08-01 코와 가부시키가이샤 피로 예방 및/또는 회복을 위한 의약
US9522161B2 (en) * 2010-10-26 2016-12-20 Advanced Bio Development, Inc. Performance enhancing composition and method of delivering nutrients
CN113142581B (zh) * 2010-12-23 2025-07-22 阿马曾提斯公司 用于改善线粒体功能的组合物和方法
US20140044690A1 (en) * 2012-08-08 2014-02-13 University Of South Florida High-Energy Compounds for Use in Alzheimer's and Other Neurodegenerative Diseases
BR112015005199B1 (pt) * 2012-09-10 2022-09-06 Metabolic Technologies, Inc Composição, e, método para fornecer um benefício a um animal em necessidade do mesmo
WO2014106860A2 (en) * 2013-01-03 2014-07-10 Laila Nutraceuticals Synergistic dietary supplement compositions for enhancing physical performance and energy levels
US10888576B2 (en) * 2018-10-08 2021-01-12 Metabolic Technologies, Inc. Composition of HMB and ATP and methods of use
WO2021046357A1 (en) * 2019-09-05 2021-03-11 Jiangyin Tsi Pharmaceutical Co., Ltd. Compositions containing adenosine triphosphate (atp) and methods of use

Similar Documents

Publication Publication Date Title
JP2023541432A5 (cg-RX-API-DMAC10.html)
EP3630072A1 (en) Methods and compositions for treating excessive sleepiness
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
TWI455723B (zh) 納曲酮及安非他酮於治療超重或肥胖病患之用途
JP2022551696A5 (cg-RX-API-DMAC10.html)
JP2019517542A5 (cg-RX-API-DMAC10.html)
JP2012521435A5 (cg-RX-API-DMAC10.html)
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
JP2018507243A5 (cg-RX-API-DMAC10.html)
MXPA05012810A (es) Formas de dosis oral de memantina.
RU2007127499A (ru) Таблетированные композиции, содержащие cci-779 в биодоступной при пероральном введении форме
RU2010109359A (ru) Азитромицин для лечения кожных заболеваний
JP2010538066A5 (cg-RX-API-DMAC10.html)
JP2022521233A5 (cg-RX-API-DMAC10.html)
JP2024542984A5 (cg-RX-API-DMAC10.html)
BRPI0510895A (pt) formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
JP2016505050A5 (cg-RX-API-DMAC10.html)
JP2024531799A5 (cg-RX-API-DMAC10.html)
JP2011500589A5 (cg-RX-API-DMAC10.html)
JP2022553888A5 (cg-RX-API-DMAC10.html)
EP4045058A1 (fr) Utilisation de nictotinamide mononucléotide (nmn) pour la prevention et/ou le traitement de la polyarthrite rhumatoïde et compositions correspondantes
JP2025508098A5 (cg-RX-API-DMAC10.html)
JP2022177119A5 (cg-RX-API-DMAC10.html)
JP2024522163A5 (cg-RX-API-DMAC10.html)